• Home

  • Services

  • Contact

  • More

    © 2018 First Apex International

    Importance of Investor Relations for a Small Biotech Company

    June 17, 2015

    |

    FAI

    While biotech companies often make developing a well thought out investor relations campaign an essential part of their business model, it is also vital for them to understand the real importance of a properly planned IR/PR campaign. With proper planning and guidance, a biotech company's good PR and IR can play a positive role in its success as a public company.

    Why is Investor relations important?

     

    A source of regular funding

     

    Most biotech companies are constantly searching for funding. Maintaining a well-planned investor relations campaign brings the company one step closer to having readily available capital to fund current and future projects

     

    Attracting new investors

     

    Regularly seeking to improve Investor relations publicizes the zeal and energy your biotech company is putting into developing its assets. This ultimately attracts more potential investors. When investors witness a company's active involvement with its shareholders, these investors tend to favor the company with a more open line of communication over their competitors who are lacking in this area.

     

    To avoid investor abandonment

     

    Many small biotech companies abandon their early staged product ideas overtime. This sometimes shows the lack of proper investor relations management. Although there are various factors behind why biotech companies lose faith in certain ventures, insufficient funding or weak investor support are one of the most common reasons. As most biotech companies are not financially self-sufficient in their early stages, the only way to get their product to market is through investor support. Thus, maintaining investor relations becomes crucial in such circumstances.

     

    To build a bond of trust with investors

     

    Building a relationship of trust with investors is one of the most important aspects biotechs should be focusing on. Stringent government regulation in conjunction with relatively sophisticated business models and technical processes are several key factors that cause biotech companies to appear unattractive to certain investors. However, through senior management backed investor relations campaigns and by properly conveying their message to current and potential shareholders, their company will be better positioned over its competitors.

    Please reload

    Featured Posts

    Oil Extends Crash Into New Year as Glut Fear Deepens By Reuters 1/5/15 at 2:04 PM

    January 6, 2015

    Paul Sonkin of Columbia Business School Speaks on Micro Cap Value Investing

    September 1, 2014

    Alibaba's Jack Ma's Original Sales Pitch 1999

    January 8, 2015

    1/3
    Please reload

    Recent Posts

    Small/Microcap Legal Counsel

    October 3, 2015

    Where Activist Investors and Investor Relations Intersect

    August 26, 2015

    Reengineering IR

    August 5, 2015

    Chinese Dragon in Firefighting Mode

    July 16, 2015

    Importance of Investor Relations for a Small Biotech Company

    June 17, 2015

    Alibaba's Jack Ma's Original Sales Pitch 1999

    January 8, 2015

    Oil Extends Crash Into New Year as Glut Fear Deepens By Reuters 1/5/15 at 2:04 PM

    January 6, 2015

    Paul Sonkin of Columbia Business School Speaks on Micro Cap Value Investing

    September 1, 2014

    Please reload

    Archive

    October 2015 (1)

    August 2015 (2)

    July 2015 (1)

    June 2015 (1)

    January 2015 (2)

    September 2014 (1)

    Please reload

    Search By Tags

    china

    oil platform

    paul sonkin on micro caps

    shannghai index

    shenzhen stock exchange

    stock market

    Please reload

    Follow Us
    • Facebook Basic Square
    • Twitter Basic Square
    • Google+ Basic Square